arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Allogene Therapeutics, Inc.

ALLO
$1.68 ▼ -0.03 (-1.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Allogene Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $552.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -8.5% ↗
FCF / Share $-0.10 ↘
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.64M
— —
Net Income Profit after all expenses
$-42.61M
↑ +28.7% —
Operating Margin Operating profit as % of sales
2.3%
↑ +102.6% —
FCF / Share Free cash flow per share
$-0.10
↓ -81.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
13
Cash Quality ↑
53

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 35 quarters